EG24019A - Optimised formulation of tobramycin for aerosolization - Google Patents

Optimised formulation of tobramycin for aerosolization

Info

Publication number
EG24019A
EG24019A EG2002060744A EG2002060744A EG24019A EG 24019 A EG24019 A EG 24019A EG 2002060744 A EG2002060744 A EG 2002060744A EG 2002060744 A EG2002060744 A EG 2002060744A EG 24019 A EG24019 A EG 24019A
Authority
EG
Egypt
Prior art keywords
aerosolization
tobramycin
formulation
optimised
optimised formulation
Prior art date
Application number
EG2002060744A
Other languages
English (en)
Inventor
Chiara Malvolti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24019(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of EG24019A publication Critical patent/EG24019A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
EG2002060744A 2001-07-02 2002-06-29 Optimised formulation of tobramycin for aerosolization EG24019A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01116071A EP1273292B1 (fr) 2001-07-02 2001-07-02 Formulation optimisée de tobramycine pour administration sous forme d'aérosol

Publications (1)

Publication Number Publication Date
EG24019A true EG24019A (en) 2008-03-25

Family

ID=8177921

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2002060744A EG24019A (en) 2001-07-02 2002-06-29 Optimised formulation of tobramycin for aerosolization

Country Status (27)

Country Link
US (5) US6987094B2 (fr)
EP (1) EP1273292B1 (fr)
JP (1) JP4262086B2 (fr)
KR (1) KR100910888B1 (fr)
CN (1) CN1234346C (fr)
AT (1) ATE267591T1 (fr)
AU (1) AU2002319226B2 (fr)
BG (1) BG66328B1 (fr)
BR (1) BRPI0211320B8 (fr)
CA (1) CA2452638C (fr)
CZ (1) CZ299348B6 (fr)
DE (1) DE60103527T2 (fr)
DK (1) DK1273292T3 (fr)
EA (1) EA006068B1 (fr)
EE (1) EE05392B1 (fr)
EG (1) EG24019A (fr)
ES (1) ES2222294T3 (fr)
HK (1) HK1068784A1 (fr)
HU (1) HU230807B1 (fr)
PL (1) PL202598B1 (fr)
PT (1) PT1273292E (fr)
SI (1) SI1273292T1 (fr)
SK (1) SK285806B6 (fr)
TN (1) TNSN03149A1 (fr)
TR (1) TR200401980T4 (fr)
WO (1) WO2003004005A1 (fr)
ZA (1) ZA200400026B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
NZ546821A (en) * 2003-10-15 2009-04-30 Pari Pharma Gmbh Liquid preparation containing tobramycin
US8442280B2 (en) * 2004-01-21 2013-05-14 Edda Technology, Inc. Method and system for intelligent qualitative and quantitative analysis of digital radiography softcopy reading
DK2266534T3 (da) 2004-05-17 2013-01-14 Gilead Sciences Inc Aerosoliseret fosfomycin/tobramycin-kombination til behandling af cystisk fibrose
US8524734B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
BRPI0616642A2 (pt) 2005-09-29 2011-06-28 Nektar Therapeutics formulações de antibióticos, doses unitárias, kits e métodos
US20090246146A1 (en) * 2008-01-25 2009-10-01 Botond Banfi Halides in the treatment of pathogenic infection
KR20110091510A (ko) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
CA2739893C (fr) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation de levofloxacine pour reduire une inflammation des poumons
WO2010096242A1 (fr) * 2009-02-18 2010-08-26 Aradigm Corporation Formulations modulées par le ph destinées à une administration pulmonaire
RU2015130524A (ru) 2009-09-04 2018-12-21 Раптор Фармасьютикалз Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
EP2388008A1 (fr) 2010-05-14 2011-11-23 Combino Pharm, S.L. Formulation aqueuse stable et sans conservateurs pour l'administration par aérosol contenant de la tobramycine
CN103052392A (zh) * 2010-07-12 2013-04-17 赛利亚医药公司 通过氨基糖苷气雾给药治疗肺部感染
CN103228282A (zh) * 2010-09-13 2013-07-31 苏黎世大学 细菌感染性疾病的治疗
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
PL2567691T3 (pl) 2011-09-12 2015-05-29 Meiji Seika Pharma Co Ltd Kompozycje wodne obejmujące arbekacynę
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
CN105534961B (zh) * 2015-12-30 2019-06-04 孙红娟 妥布霉素吸入溶液及其制备方法
CN105616345B (zh) * 2016-03-01 2018-08-21 上海方予健康医药科技有限公司 一种妥布霉素吸入组合物及其制备方法和用途
WO2018107020A1 (fr) * 2016-12-09 2018-06-14 Enbiotix, Inc. Potentialisation d'aminoglycoside pour le traitement d'une infection bactérienne pulmonaire
CN108014099B (zh) * 2017-12-15 2019-03-01 武汉兴华智慧医药科技有限公司 一种吸入用妥布霉素溶液及其制备方法
GB2565941A (en) * 2018-11-27 2019-02-27 Norton Healthcare Ltd A process for preparing a formulation
CN113018443B (zh) * 2019-12-27 2022-09-13 海南斯达制药有限公司 治疗呼吸系统疾病的药物组合物及其制备方法
CN113952320B (zh) * 2021-09-18 2022-03-18 健康元药业集团股份有限公司 一种包含妥布霉素吸入溶液的药物组件及其用途

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
MX3864E (es) 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
CA2098298A1 (fr) 1990-12-19 1992-06-20 Susan M. Milosovich Formulations en aerosol
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
EP0585379B1 (fr) 1991-05-21 1998-09-30 Abbott Laboratories Dispositif d'inhalation en aerosol
CA2116579A1 (fr) 1991-08-29 1993-03-18 Christoph Klein Dispositif medical d'inhalation de doses d'aerosol
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressed aerosol preparations
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
DE4230876A1 (de) 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
WO1994013263A1 (fr) 1992-12-09 1994-06-23 Jager Paul D Formulations en aerosol de solutions medicinales stabilisees
SE9203743D0 (sv) 1992-12-11 1992-12-11 Astra Ab Efficient use
AU4066693A (en) 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
AU679510B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing a diol-diacid derived dispersing aid
DE69413955T2 (de) 1993-03-17 1999-04-01 Minnesota Mining & Mfg Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
WO1995017195A1 (fr) 1993-12-20 1995-06-29 Minnesota Mining And Manufacturing Company Compositions d'aerosols a base de flunisolide
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
NZ298169A (en) 1994-12-22 1999-09-29 Astra Ab Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5653961A (en) 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
CA2361954C (fr) 1995-04-14 2003-07-08 Smithkline Beecham Corporation Inhalateur doseur d'albuterol
KR19980703850A (ko) 1995-04-14 1998-12-05 그레이엄브레레톤 베클로메타손 디프로피오네이트용 계량 흡입기
EE04004B1 (et) 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Flutikasoonpropionaati doseeriv inhalaator
BR9604977A (pt) 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador de dose medida sistema inalador de dose medida e uso do mesmo
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
WO1998001147A1 (fr) 1996-07-08 1998-01-15 Rhone-Poulenc Rorer Limited Formulation d'une solution d'aerosol medicinal de cyclosporine a
WO1998003533A1 (fr) 1996-07-24 1998-01-29 Oligos Etc. And Oligos Therapeutics, Inc. Oligonucleotides anti-sens utilises comme agents antibacteriens
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
CA2273835A1 (fr) 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Compositions pharmaceutiques et leurs dispositifs d'administration
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
WO1998034595A1 (fr) 1997-02-05 1998-08-13 Jago Research Ag Formulations medicales pour aerosols
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
BR7702049U (pt) 1997-09-05 1999-09-14 Chiesi Farma Spa Bico pulverizador para utilização em inalador oral para medicamentos aerossóis
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6045784A (en) 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
DE19847969A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
EP1862164A3 (fr) 1998-11-13 2012-12-26 Jagotec AG Poudre sèche pour inhalation
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
HU230804B1 (hu) 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
EP1340492A1 (fr) 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique
EP1415647A1 (fr) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Beta-2-agonistes à activité de longue durée dans une formulation ultrafine
JP2005523905A (ja) 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
US20050083693A1 (en) * 2003-10-21 2005-04-21 Timothy Garrett Flag illumination fixture

Also Published As

Publication number Publication date
PL202598B1 (pl) 2009-07-31
CA2452638C (fr) 2010-10-05
JP4262086B2 (ja) 2009-05-13
EP1273292B1 (fr) 2004-05-26
CN1529589A (zh) 2004-09-15
CZ20033580A3 (cs) 2004-10-13
EP1273292A1 (fr) 2003-01-08
US20040186064A1 (en) 2004-09-23
SK16432003A3 (sk) 2004-06-08
US7939502B2 (en) 2011-05-10
BG66328B1 (bg) 2013-06-28
US20050163722A1 (en) 2005-07-28
HK1068784A1 (en) 2005-05-06
CN1234346C (zh) 2006-01-04
BRPI0211320B1 (pt) 2015-08-18
TNSN03149A1 (en) 2005-12-23
TR200401980T4 (tr) 2004-09-21
EA200301305A1 (ru) 2004-06-24
US20110212912A1 (en) 2011-09-01
BG108475A (en) 2005-02-28
BR0211320A (pt) 2004-09-28
KR20040018403A (ko) 2004-03-03
US6987094B2 (en) 2006-01-17
DK1273292T3 (da) 2004-10-04
PL367139A1 (en) 2005-02-21
CZ299348B6 (cs) 2008-06-25
EE200400050A (et) 2004-04-15
ES2222294T3 (es) 2005-02-01
US20120184502A1 (en) 2012-07-19
HU230807B1 (hu) 2018-06-28
CA2452638A1 (fr) 2003-01-16
EA006068B1 (ru) 2005-08-25
KR100910888B1 (ko) 2009-08-05
EE05392B1 (et) 2011-04-15
ZA200400026B (en) 2005-03-30
SK285806B6 (sk) 2007-08-02
HUP0400387A2 (hu) 2004-09-28
WO2003004005A1 (fr) 2003-01-16
DE60103527D1 (de) 2004-07-01
AU2002319226B2 (en) 2006-07-06
DE60103527T2 (de) 2005-06-16
US8168598B2 (en) 2012-05-01
SI1273292T1 (en) 2004-12-31
JP2004535454A (ja) 2004-11-25
US20100098642A1 (en) 2010-04-22
US7696178B2 (en) 2010-04-13
ATE267591T1 (de) 2004-06-15
BRPI0211320B8 (pt) 2021-05-25
PT1273292E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
HK1068784A1 (en) Optimised formulation of tobrarmycin for aerosolization
HK1126134A1 (en) Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SI1458360T1 (sl) Pulmonalno dajanje aminoglikozidov
WO2002054868A3 (fr) Apport pulmonaire d'agents antifongiques polyene
WO2001089496A3 (fr) Compositions antibiotiques destinees au traitement des yeux, oreilles et nez
BR0012750A (pt) Agente de limpeza para superfìcies cerâmicas vìtreas
BR0116757A (pt) Método para o tratamento de infecções pulmonares causadas por bactérias gram-negativas e composição para inalação farmaceuticalmente aceitável.
ATE183080T1 (de) Neue und verbesserte aminoglykosidformulierung als aerosol
HK1111883A1 (en) Use of a composition for preventing or treating respiratory infections and acute otitis media in infants
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
DE60307860D1 (de) Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
CA2527365A1 (fr) Compositions de prevention et de traitement de symptome de type rhume et grippe comprenant du zinc chelate
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
ES2133722T3 (es) Utilizacion de dextranos simples o conjugados para la fabricacion de un medicamento para prevenir o reducir el riesgo de infeccion de germenes patogenos bacterianos.
WO2003032985A3 (fr) Nouvelles methodes de traitement d'infections bacteriennes et fongiques locales
AU2003294565A8 (en) Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
WO2006033713A3 (fr) Procedes destines a l'inhalation de ciprofloxacine
BR0100228A (pt) Macrolìdeos com 13 e 14 elementos antibacterianos e procinéticos e seus intermediários
DK1157688T3 (da) Antibakterielle vandige ophthalmiske formuleringer med ofloxacin og chitosan
WO2004032825A3 (fr) Utilisation d'acides 2,3 alkylcarbonyloxybenzoiques pour le traitement du charbon
AR022262A1 (es) Formula bactericida de amplio espectro en soluciones concentradas y diluidas
TW200503734A (en) New use of soluble p-selectin and anthrax lethal toxin